Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Liabilities and Shareholders Equity (2016 - 2025)

Amicus Therapeutics' Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $949.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 21.0% year-over-year to $949.9 million, compared with a TTM value of $3.4 billion through Dec 2025, up 12.52%, and an annual FY2025 reading of $949.9 million, up 21.0% over the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $949.9 million at Amicus Therapeutics, up from $868.8 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $956.7 million in Q3 2021, with the low at $700.5 million in Q1 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $800.5 million, with a median of $786.7 million recorded in 2021.
  • Year-over-year, Liabilities and Shareholders Equity decreased 20.61% in 2022 and then increased 21.0% in 2025.
  • Tracing FOLD's Liabilities and Shareholders Equity over 5 years: stood at $905.1 million in 2021, then fell by 19.99% to $724.2 million in 2022, then grew by 7.42% to $777.9 million in 2023, then increased by 0.92% to $785.0 million in 2024, then rose by 21.0% to $949.9 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Liabilities and Shareholders Equity are $949.9 million (Q4 2025), $868.8 million (Q3 2025), and $815.3 million (Q2 2025).